---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089295"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:15:09.736478+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BrainStorm Q2 net loss narrows to $2.5M; FDA alignment on NurOwn Phase 3b trial CMC

## Summary
- Net loss for Q2 2024 was $2.5M ($0.04/sh), compared to $5.3M ($0.13/sh) in Q2 2023.
- Cash, cash equivalents, and restricted cash were $3.65M as of June 30, 2024.
- Reached FDA alignment on CMC aspects for Phase 3b NurOwn trial in ALS, following SPA agreement in April.
- Appointed Hartoun Hartounian Ph.D. as EVP/COO and promoted Dr. Bob Dagher to EVP/CMO.
- Completed registered direct offering raising $4.0M gross proceeds from single institutional investor.

## SEC filing metadata
- accession: 0001104659-24-089295
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465924089295/0001104659-24-089295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465924089295/tm2421455d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089295
- JSON: https://secwatch.observer/filing/0001104659-24-089295.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.